|
Name |
Pimara-8(14),15-diene
|
Molecular Formula | C20H32 | |
IUPAC Name* |
(4aS,4bS,7S,10aS)-7-ethenyl-1,1,4a,7-tetramethyl-3,4,4b,5,6,9,10,10a-octahydro-2H-phenanthrene
|
|
SMILES |
C[C@]1(CC[C@H]2C(=C1)CC[C@@H]3[C@@]2(CCCC3(C)C)C)C=C
|
|
InChI |
InChI=1S/C20H32/c1-6-19(4)13-10-16-15(14-19)8-9-17-18(2,3)11-7-12-20(16,17)5/h6,14,16-17H,1,7-13H2,2-5H3/t16-,17-,19+,20+/m0/s1
|
|
InChIKey |
XDSYKASBVOZOAG-RAUXBKROSA-N
|
|
Synonyms |
Pimaradiene; Pimara-8(14),15-diene; 1686-61-9; 8(14),15-sandaracopimaradiene; sandaracopimara-8(14),15-diene; [4aS-(4aalpha,4bbeta,7beta,10abeta)]-7-ethenyl-1,2,3,4,4a,4b,5,6,7,9,10,10a-dodecahydro-1,1,4a,7-tetramethylphenanthrene; C06086; CHEBI:8210; DTXSID701319108; (4aS,4bS,7S,10aS)-7-ethenyl-1,1,4a,7-tetramethyl-3,4,4b,5,6,9,10,10a-octahydro-2H-phenanthrene; 13-Vinyl-16,17-dinorabieta-8(14)-ene; Q27107957
|
|
CAS | 1686-61-9 | |
PubChem CID | 440909 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 272.5 | ALogp: | 7.0 |
HBD: | 0 | HBA: | 0 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 0.0 | Aromatic Rings: | 3 |
Heavy Atoms: | 20 | QED Weighted: | 0.501 |
Caco-2 Permeability: | -4.553 | MDCK Permeability: | 0.00001530 |
Pgp-inhibitor: | 0.72 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.005 | 20% Bioavailability (F20%): | 0.996 |
30% Bioavailability (F30%): | 0.979 |
Blood-Brain-Barrier Penetration (BBB): | 0.029 | Plasma Protein Binding (PPB): | 96.42% |
Volume Distribution (VD): | 1.084 | Fu: | 3.55% |
CYP1A2-inhibitor: | 0.222 | CYP1A2-substrate: | 0.381 |
CYP2C19-inhibitor: | 0.379 | CYP2C19-substrate: | 0.819 |
CYP2C9-inhibitor: | 0.476 | CYP2C9-substrate: | 0.22 |
CYP2D6-inhibitor: | 0.648 | CYP2D6-substrate: | 0.122 |
CYP3A4-inhibitor: | 0.958 | CYP3A4-substrate: | 0.61 |
Clearance (CL): | 5.475 | Half-life (T1/2): | 0.047 |
hERG Blockers: | 0.032 | Human Hepatotoxicity (H-HT): | 0.305 |
Drug-inuced Liver Injury (DILI): | 0.034 | AMES Toxicity: | 0.002 |
Rat Oral Acute Toxicity: | 0.212 | Maximum Recommended Daily Dose: | 0.904 |
Skin Sensitization: | 0.173 | Carcinogencity: | 0.457 |
Eye Corrosion: | 0.911 | Eye Irritation: | 0.773 |
Respiratory Toxicity: | 0.752 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002266 | 0.514 | D0Z1XD | 0.289 | ||||
ENC001452 | 0.465 | D0I2SD | 0.268 | ||||
ENC000956 | 0.463 | D0SC8F | 0.264 | ||||
ENC003102 | 0.442 | D0L2LS | 0.263 | ||||
ENC003145 | 0.442 | D0U3GL | 0.261 | ||||
ENC002923 | 0.437 | D0Q6NZ | 0.260 | ||||
ENC002141 | 0.434 | D08QKJ | 0.255 | ||||
ENC000946 | 0.430 | D04GJN | 0.255 | ||||
ENC002608 | 0.430 | D06XMU | 0.253 | ||||
ENC002041 | 0.417 | D0G8BV | 0.253 |